Recent studies have implicated interferon signaling in the regulation of cellular senescence. However, the role of specific interferon-inducible proteins in cellular senescence remains to be defined. Here we report that IFI 16, an interferon-inducible transcriptional modulator from the p200-protein family, contributes to cellular senescence of prostate epithelial cells. Normal human prostate epithelial cells (PrEC) in culture expressed detectable levels of IFI 16, and the levels increased more than fourfold when cells approached cellular senescence. Consistent with a role of IFI 16 in cellular senescence, human prostate cancer cell lines either did not express IFI 16 or expressed a variant form, which was primarily detected in the cytoplasm of prostate cancer cells and not in the nucleus. Moreover, overexpression of functional IFI 16 in human prostate cancer cell lines inhibited colony formation. Additionally, ectopic expression of IFI 16 in clonal prostate cancer cell lines was associated with a senescence-like phenotype, production of senescence-associated b-galactosidase (a biochemical marker for cellular senescence), and reduction of S-phase cells in culture. Importantly, upregulation of p21 WAF1 and inhibition of E2F-stimulated transcription accompanied inhibition of cell growth by IFI 16 in prostate cancer cell lines. Collectively, our observations support the idea that increased levels of IFI 16 in PrECs contribute to senescence-associated irreversible cell growth arrest.
Introduction
Normal somatic cells have a limited capacity for cell division in culture and eventually enter a state of irreversible proliferative arrest, termed replicative senescence or cellular senescence (Hayflick, 1965; Smith and Pereira-Smith, 1996) . Accumulating data suggest that the irreversible cell growth arrest associated with cellular senescence represents a major barrier, analogous to apoptosis, which cells must circumvent to become malignant (Campisi, 2001) . Therefore, identification of pathways, which regulate cellular senescence, and elucidation of the molecular mechanisms by which cells can bypass cellular senescence, are critical to the understanding of development of prostate cancer.
Interferons (IFNs), a family of cytokines, are potent inhibitors of cell growth both in vitro and in vivo (Gutterman, 1994; Borden et al., 2000) . IFNs also exhibit antitumor activity (Borden et al., 2000; Jonasch and Haluska, 2001) . As IFN-inducible proteins mediate the growth-inhibitory activities of IFNs (Sen and Lengyel, 1992; Stark et al., 1998) , it is important to define their role in pathways contributing to irreversible cell growth arrest.
Recent studies involving unbiased approaches, such as cDNA-microarray analyses (Shou et al., 2002) or serial analysis of gene expression (SAGE) (Untergasser et al., 2002) , have revealed that IFN signaling may play an important role in cellular senescence of human prostate epithelial cells. For example, expression of a set of IFN-activatable genes is upregulated during the onset of cellular senescence in human prostate epithelial cells (HPrECs) (Untergasser et al., 2002) . Moreover, the loss of expression of IFN-activatable genes is correlated with development of prostate cancer (Shou et al., 2002) . Although these studies suggest the role of IFN-inducible proteins in cellular senescence of PrECs, role of specific IFN-inducible proteins in cellular senescence remains to be defined.
The 200-gene family encodes one family (the p200 family) of IFN-inducible proteins (Lengyel et al., 1995; Landolfo et al., 1998; Johnstone and Trapani, 1999) . The gene family includes in mice Ifi202a, Ifi202b, Ifi203, Ifi204, and D3 genes; and in humans IFI16, MNDA, and AIM2 genes (Lengyel et al., 1995; Wang et al., 1999) . The murine genes are located on the long arm of mouse chromosome 1 (Lengyel et al., 1995) . Interestingly, this part of mouse chromosome is syntenic to human chromosome 1 (Kingsmore et al., 1989) . Notably, the human genes, including the IFI 16 gene, are located in the 1q22 region, predicted to harbor a gene(s) with a role in cellular senescence (Hensler et al., 1994; Karlsson et al., 1996) . Consistent with this prediction, expression of the AIM2 gene is lost in human fibroblasts derived from Li-Fraumeni patients during immortalization (Kulaeva et al., 2003) .
The p200-family proteins share at least one repeat of partially conserved 200-amino-acid residues (HIN-200 domain) (Lengyel et al., 1995; Johnstone and Trapani, 1999) . The protein p202a (hereafter referred as p202) is the best-characterized family member and contains two 200-amino-acid repeats (Choubey, 2000; Choubey and Kotzin, 2002) . Of note, these repeats in p202 bind several transcription factors (Choubey, 2000) , raising the possibility that 200-amino-acid repeats serve as scaffolds to assemble large protein complexes modulating transcription of the target genes. Additionally, some of these proteins, including p204 and IFI 16, also share a newly identified protein domain named DAPIN/PYR-IN/CARD in their N-terminus (Choubey and Kotzin, 2002) . The domain is thought to be involved in proteinprotein interactions and is found in several deathassociated proteins (Fairbrother et al., 2001; Staub et al., 2001) . The presence of a CARD domain and two HIN-200 domains in IFI 16 protein is consistent with its potential role as a scaffold protein.
Studies have indicated that ectopic expression of p200-family proteins, such as p202 and p204, in a variety of cultured cells results in retardation of cell proliferation (Choubey, 2000) . Interestingly, inhibition of cell growth by p202 (Choubey and Kotzin, 2002) and p204 (Hertel et al., 2000) appears to depend on Rb tumor-suppressor protein. Consistent with a role for p200-family proteins in cell-growth regulation, there are indications that viral oncoproteins functionally inactivate p202 . Expression of AIM2 is lost by frame-shift mutations in colorectal tumors (Mori et al., 2001) , and loss of MNDA expression in prostate carcinoma is linked to progression to more aggressive metastatic prostate cancer (Varambally et al., 2002) . These observations support the idea that the loss of function of p200-family proteins, by providing the growth advantage to the affected cells, may contribute to the development of cancer.
The protein IFI 16 is primarily a nuclear phosphoprotein (80-85 kDa), which contains two repeats of the 200-amino acids (one a-type and one b-type) and a serine-threonine-proline (S/T/P)-rich spacer region separates the two repeats (Johnstone and Trapani, 1999) . The size of the spacer region in IFI 16 is regulated by mRNA splicing and can contain one, two, or three copies of highly conserved 56-amino-acid S/T/P domain encoded by distinct exons, resulting in three differentsize proteins: A, B, and C (Johnstone et al., 1998) . The protein IFI 16 is primarily nuclear in lymphoid cells (Dawson and Trapani, 1995) . Importantly, recent analyses of IFI 16 expression in several human tissues by immunohistochemistry revealed that expression of IFI 16 is not restricted to cells of hematopoietic origin (Gariglio et al., 2002; Wei et al., 2003) . Of note, IFN induction of IFI 16 in hematopoietic cells appears to be cell-type-and donor-specific (Schlaak et al., 2002) .
A study has revealed that IFN induction of IFI 16 in human melanoma cell lines correlates well with inhibition of cell growth (Certa et al., 2001) . As the IFI 16 gene is located in the region 1q22, predicted to harbor a senescence gene(s) (Hensler et al., 1994; Karlsson et al., 1996) , we investigated the role of IFI 16 in cellular senescence of prostate epithelial cells. Our observations provide support for the idea that the loss of IFNinducible IFI 16 function in normal human prostate epithelial cells contributes to bypassing of cellular senescence, thus, contributing to development of prostate cancer.
Results

Expression of IFI 16 is detectable in normal human prostate
Recent immunohistochemical analyses of IFI 16 protein in normal human tissues revealed that its expression is not restricted to hematopoietic cells (Gariglio et al., 2002; Wei et al., 2003) . Additionally, hybridization of IFI 16 cDNA probe to a multiple tissue Northern blot revealed that IFI 16 mRNA expression is relatively high in several human tissues, including the prostate (Wei et al., 2003) . Therefore, we tested whether expression of IFI 16 protein is detectable in normal human tissues. Our experiments using immunoblotting indicated that expression of IFI 16 is readily detectable in extracts derived from normal human prostate, ovary, and breast tissues (see Figure 1) . As a control, we also determined levels of double-stranded RNA-dependent protein kinase (PKR), a well-known IFN-inducible protein (Sen and Lengyel, 1992) , which were also detectable in human liver-, prostate-, ovary-, and breast-derived protein extracts.
Expression of IFI 16 is detectable in normal PrECs and its levels increase after IFN treatment or during cellular senescence As expression of IFI 16 was detectable in extracts derived from normal prostate, we sought to determine whether expression of IFI 16 was detectable in normal human PrECs in culture. For this purpose, we purchased PrECs in culture (from two different donors). These PrECs have been shown to exhibit several immunophenotypic features consistent with prostate (Garraway et al., 2003) . As shown in Figure 2 , IFI 16B form (the middle protein band) was predominantly detected in proliferating PrECs at an early passage (passage 4). Notably, treatment of cells with IFN-a or g resulted in further induction of IFI 16 (compare lane 3 with 1). As a positive control for IFN treatment, we also determined levels of PKR. As shown in Figure 2 , IFN treatment of cells also produced increases in the levels of PKR.
To further investigate the role of IFI 16 in prostate epithelial cell growth, we compared basal levels of IFI 16 in extracts derived from normal PrECs at different passages: cells proliferating actively (passage 4; cells were small and polygonal), cells (30-40%) appearing flattened and round (passages 6 and 7), and most of the cells (65-75%) appearing large, flattened, and round (passage 8). As shown in Figure 3 , basal levels of IFI 16 increased with increases in the number of cell passages. Furthermore, with increases in the passage number of prostate epithelial cells, the levels of cyclin D1 decreased (not shown) and the levels of p21 WAF1 and p16
INK4a
increased (see Figure 3) . Since the PC-3 cells express detectable levels of IFI 16 mRNA and protein, we isolated cDNA coding for the IFI 16B protein (because the B form of IFI 16 is predominant in these cells) and determined its sequence (GenBank accession number for the sequence is AY138863). Next, we compared the sequence with IFI 16 gene sequences in the GenBank to identify single nucleotide polymorphisms (SNPs) in the IFI 16 gene expressed in cells of PC-3 cell line. This approach revealed that IFI 16B coding sequence from the PC-3 cell line contains six previously identified SNPs in the GenBank, resulting in the substitution of six amino acids in the IFI 16B protein (see Figure 5 ).
Although the functional significance of SNPs in the IFI 16 gene, which is expressed in the PC-3 prostate cancer cell line, remains unknown, the nonconservative amino-acid substitutions, such as His to Asp (in the CARD domain), Arg to Ser, Ser to Tyr, and Asn to Thr, in the IFI 16 protein sequence may affect its structure and/or function. Consistent with this prediction, we found that IFI 16 protein was primarily detected in the cytoplasm of PC-3 cells and not in the nucleus ( Figure 6 , right panel). As expected, in PrECs IFI 16 protein was detected exclusively in the nucleus ( Figure 6 , left panel). This observation supports the idea that mislocalization of IFI 16 in the cytoplasm of human prostate cancer cells could inactivate IFI 16 function.
Ectopic expression of IFI 16 in prostate cancer cell lines inhibits colony formation
Inhibition of cell growth by murine members of p200-family proteins depends on the retinoblastoma tumorsuppressor protein pRb (Choubey and Kotzin, 2002) . Moreover, IFI 16 stimulates the transcriptional activity of p53 (Johnstone et al., 2000) . Therefore, we chose to compare the inhibition of colony formation by IFI 16 in three well-characterized human prostate cancer cell lines (Webber et al., 1997) , differing in their status of Rb and p53 functions: DU-145 (harboring nonfunctional Rb and p53), PC-3 (harboring functional Rb but mutant p53), and LNCaP (harboring functional Rb and p53). For this purpose, we first compared the transfection efficiencies between the vector (pCMV) and pCMV-IFI 16B. Using FuGene-6 as a transfection reagent, we transfected pCMV or pCMV IFI16 plasmid along with pCMV-b-gal plasmid (encoding b-galactosidase; in 10 : 1 ratio) into DU-145 cells and stained cells for bgalactosidase activity. Counting of the blue cells indicated that the transfection efficiencies between the two plasmids were comparable (B34 and B38%, respectively) in two independent experiments. Next, the above three prostate cancer cell lines were transfected either with vector pCMV or pCMV-IFI16B plasmid in the same experiment. Transfectants were selected in G418 for about 2 weeks and colonies stained, and counted. As shown in Figure 7 , transfection of pCMV-IFI 16B plasmid in the three cell lines resulted in inhibition of colony formation, as compared to vectortransfected cells (the number of colonies was normalized for differences in the transfection efficiencies). However, the extent of colony inhibition varied: the maximum inhibition (490%) was seen in LNCaP cells; minimum We found similar results in two sets of experiments.
Restoration of IFI 16 function in the PC-3 cell line results in a senescence-like phenotype
Overexpression of IFI 16 in cells of PC-3 cell line resulted in a significant (B50%) inhibition of colony formation. Moreover, the levels of IFI 16 increased in cultured normal PrECs when they approached replicative senescence. Therefore, to determine whether the restoration of IFI 16 function in PC-3 cells results in a senescence-like phenotype, we isolated several (430) independent cell clones of PC-3 cells (overexpressing IFI 16B) and maintained them in culture. Interestingly, culture of these cell clones after about 18-34 population doublings exhibited morphological changes in cells: cells appeared enlarged and flattened with increased granularity (see Figure 8a) . (It is known that, after expression of a senescence-inducing gene in human immortal cell lines, not all cell clones cease cell proliferation in a synchronous manner; see Campisi, 2001 .) We chose three independent cell clones (indicated as S-1, S-2, and S-3, respectively) for further characterization with respect to the expression levels of IFI 16 (and other cell-cycle-regulatory proteins), expression of senescenceassociated-b-gal (pH 6.0), and irreversible cell growth arrest in the G 1 phase of cell cycle. Overexpression of IFI 16 in three cell clones (S-1, S-2, and S-3) resulted in a senescence-like phenotype over the timescale of the experiment. Importantly, cells of all the three clones expressed significantly higher levels of IFI 16 as compared to vector-transfected cells (pooled cell clones) and IFI 16 was primarily detected in the nuclear fraction of cells (data not shown). Of note, we detected two IFI 16 protein bands in extracts derived from cell clones (see Figure 8b) , raising the possibility that the upper protein band arises from the phosphorylated form of IFI 16B. Moreover, the increased levels of IFI 16 correlated with increases in levels of CDKI p21 WAF1 and decreases in the levels of cyclin E. The latter is indicative of cell growth arrest in the G1 phase of cell cycle (Harbour and Dean, 2000; DeGregori, 2002) . Staining of cell clones for BrdU incorporation (to determine cell growth arrest in the G1 phase of cell cycle), in two independent experiments, revealed that, as compared to vector-transfected cells, all the three cultures of cell clones had significantly fewer cells in the S phase (see Figure 8d ). This observation was also consistent with our flow-cytometry data in which we compared the percentage of cells in the G1 phase of cell cycle between cultures of vector-transfected cells and cultures of three cell clones (data not shown). Thus, these approaches indicated that ectopic expression of functional IFI 16 in PC-3 cells resulted in irreversible cell growth arrest primarily in the G1 phase of cell cycle and a senescence-like phenotype.
Together, the above observations indicated that the expression of IFI 16 in normal prostate epithelial cells contributes to a senescence-associated irreversible cell growth arrest.
IFI 16 upregulates expression of p21 WAF1
Since ectopic expression of IFI 16 in PC-3 cells was accompanied by increases in the steady-state levels of p21 WAF1 , we tested whether IFI 16 upregulates expression of p21
WAF1
. As shown in Figure 9a , expression of IFI 16 in promoter-reporter assays (in several experiments) resulted in a dose-dependent increase in the activity of p21-luc-reporter in DU-145 cells. Consistent with this observation, increased constitutive expression of IFI 16 in stable cell clones of DU-145 cell line resulted in upregulation of p21 WAF1 (see Figure 9b ). Again, we detected two IFI 16 B protein bands, which probably represent hypo and hyperphosphorylated forms of IFI 16B. Similarly, increased expression of IFI 16B in HeLa cell line also resulted in upregulation of p21 WAF1 (data not shown). Since both PC-3 and DU-145 prostate cancer cell lines do not harbor a functional p53 (Webber et al., 1997) , these observations are consistent with p53-independent regulation of p21 WAF1 by IFI 16. Together, these observations support the idea that the interferoninducible IFI 16 inhibits cell growth of PrECs, in part, by upregulating the expression of p21 WAF1 .
IFI 16 inhibits E2F1-stimulated transcription and binds to E2F1 and Rb
The tumor suppressor Rb is known to inhibit cell growth, in part, by binding to E2Fs (E2F1, 2, and 3) and inhibiting E2F-stimulated transcription (Harbour and Dean, 2000; DeGregori, 2002) . Since IFI 16 contains an LxCxE-like motif to bind Rb, and predicted to inhibit the E2F-mediated transcription (Gribaudo et al., 1999) , in order to elucidate the molecular mechanism(s) by which IFI 16 inhibits growth of prostate epithelial cells, we tested whether IFI 16 inhibits E2F1-stimulated transcription. As shown in Figure 10a , expression of IFI 16 in promoter-reporter assays significantly (70-80%) inhibited E2F1-stimulated increases in the activity of the E2F-luc-reporter in PC-3 cell line (these cells express functional Rb).
Since binding of p202 to both E2F1 and Rb correlates with inhibition of E2F-stimulated transcriptioin (Choubey et al., 1996) , we tested whether IFI 16 could bind to E2F1 and/or Rb. For this purpose, we used the full-length (amino-acid residues 1-729) or truncated (1-159 and 127-729) IFI 16 proteins fused with the glutathione-S-transferase (GST) protein. The fusion proteins bound to GST beads were used to study interactions of IFI 16 with Rb and E2F1 proteins in vitro (in GST-pull-down assays). As shown in Figure  10b and c, the full-length IFI 16 (1-729) fused with GST, but not GST alone, selectively bound to Rb and E2F1 present in the extracts prepared from PC-3 cell line. Interestingly, the N-terminal segment (amino acids 1-159) of IFI 16, comprising the CARD/DAPIN domain, was sufficient to associate with E2F1 selectively (compare lane 3 with 2), but not Rb (compare lane 3 with 2) (see Figure 10c) . Consistent with earlier observation that deletion of the N-terminal amino acids (1-127) in IFI 16 results in increased binding of p53 to IFI 16 (Johnstone et al., 2000) , we also noted that deletion of the N-terminal amino acids (1-127) resulted in increased binding of E2F1 and Rb to IFI 16 (compare signal in lane 4 from lane 5 in Figure 10b ). Thus, these observations raise the possibility that the Nterminal region (amino acids 1-127) of IFI 16 comprising a CARD/DAPIN protein-protein interaction domain may regulate the binding of IFI 16 to p53, Rb, and E2F.
Together, these observations provide support for the hypothesis that the binding of IFI 16 to both E2F1 and Rb potentiates the Rb-E2F-mediated transcriptional repression of the growth-promoting genes. This could account for the IFI 16-mediated irreversible cell growth arrest in the G1 phase of cell cycle. 
Discussion
Ectopic expression of IFI 16 in promoter-reporter assays stimulates the transcriptional activity of p53, by binding to p53 in the C-terminus potentiating the specific DNA-binding activity (Johnstone et al., 2000) . The amino-acid sequence of IFI 16 contains an LxCxElike Rb-binding motif in the b-repeat (Lengyel et al., 1995; Johnstone and Trapani, 1999) . When ectopically expressed in human cell lines that do not express the protein, IFI 16 retards cell growth by delaying progression from G 1 to S phase of cell cycle (Johnstone and Trapani, 1999) . However, the molecular mechanisms by which IFI 16 inhibits cell proliferation remain to be elucidated.
Here we report that expression of IFI 16 is detectable in normal human prostate epithelial cells in culture and levels of IFI 16 increase significantly when cells approach cellular senescence. Consistent with its potential role in cellular senescence, prostate cancer cell lines either do not express detectable levels of IFI 16 (LNCaP and DU-145 cell lines), or express a variant form (PC-3 cell line), which was primarily detected in the cytoplasm and not in the nucleus (Figure 6 ). These observations are consistent with the possibility that the loss of IFI 16 function contributes to bypassing of cellular senescence.
Importantly, ectopic expression of IFI 16 in three prostate cancer cell lines resulted in inhibition of colony formation (see Figure 7) . Albeit the inhibition by IFI 16 varied significantly between the two cell lines that do not express IFI 16, the maximum inhibition (490%) was seen in LNCaP cells (these cells express functional Rb and p53), and minimum inhibition (B10%) was seen in DU-145 cells (these cells do not express functional Rb and p53). Interestingly, an intermediate inhibition (B50%) was seen in PC-3 cells (these cells express functional Rb but mutated p53), which express a variant form of IFI 16 (see Figure 6 ). Since these three human prostate cancer cell lines differ with respect to expression of functionals of Rb and p53 (Webber et al., 1997) , together, these observations supported an exciting possibility that IFI 16-mediated inhibition of cell growth, in part, depends on the presence of functional Rb and p53. Consistent with this possibility, we found that ectopic expression of IFI 16 in two prostate cancer cell lines (DU-145 and PC-3) resulted in upregulation of cyclin-dependent kinase p21
WAF1 (see Figures 8 and 9 ). Increases in p21 WAF1 levels inhibit phosphorylation of Rb by Cdks, resulting in inhibition of E2F-mediated transcription of its target genes (Weinberg, 1995; Harbour and Dean, 2000) . Moreover, increased levels of p21 WAF1 can also inhibit E2F-stimulated transcription independent of Rb (Dimri et al., 1996) . Therefore, it is conceivable that the IFI 16-mediated inhibition of cell growth, in part, depends on p21 WAF1 . Ectopic expression of IFI 16 in promoter-reporter assays potentiates the p53-mediated stimulation of the activity of a reporter (pww-luc) whose transcription is driven by the 5 0 -regulatory region of the p21-gene (Johnstone et al., 2000) . Moreover, the binding of IFI 16 to p53 in the C-terminus results in increased binding of p53 to DNA in gel mobility shift assays (Johnstone et al., 2000) . Although these observations suggest that IFI 16 transcriptionally upregulates expression of p21 WAF1 by activating the transcriptional activity of p53, it remains unclear whether IFI 16 also upregulates expression of p21 WAF1 by activating the transcriptional activity of other p53 family members, such as p73. Notably, we found that ectopic expression of IFI 16 in promoter-reporter assays as well as in stable prostate cancer cell lines, which do not harbor functional p53 (Webber et al., 1997) , also resulted in upregulation of p21
WAF1
. Thus, IFI 16 joins p202, the other member of the p200-family, which also upregulates p21 WAF1 by mechanisms independent of p53 (Gutterman and Choubey, 1999) .
Although it remains to be determined how IFI 16 upregulates expression of p21 WAF1 , our observations (Gartel et al., 2001) , it is conceivable that IFI 16 transcriptionally activates the p21 gene (independent of p53), in part, by relieving c-Myc-mediated transcriptional repression of p21 gene. Additionally, Rb is shown to activate the transcription of p21 gene (Decesse et al., 2001) . Therefore, binding of IFI 16 to Rb in prostate epithelial cells with functional Rb (for example, in PC-3 and LNCaP) is expected to potentiate the Rb-mediated transcriptional activation of p21 gene.
It remains to be seen whether a variant form of IFI 16, in which six amino acids of IFI 16 are substituted and is expressed in PC-3 prostate cancer cell line, is functionally defective in its ability to inhibit proliferation of prostate epithelial cells. Notably, phosphorylation status of IFI 16 is linked to its appropriate nuclear localization (Briggs et al., 2001) . Therefore, it is conceivable that the variant form of IFI 16 with additional amino acids, such as Ser 409 and Thr 667 (see Figure 5 ), which could be phosphorylated by protein kinases, behaves differently with respect to its nuclear localization and/or protein-protein interactions. Consistent with this prediction, we report that IFI 16 is mislocalized in the cytoplasm of PC-3 prostate cancer cells (Figure 6 ). Further work will be needed to address these interesting possibilities.
Studies have provided evidence that bypassing of replicative senescence in PrECs requires alterations in the p16/Rb pathway and all prostate cancer cell lines, which bypass senescence, show defects in either p16 or Rb function (Jarrard et al., 1999) . Our observations indicate that IFI 16 levels increase in normal PrECs when they approach cellular senescence (see Figure 3) . Additionally, restoration of functional IFI 16 in cells of PC-3 cell line resulted in a senescence-like phenotype (Figure 8 ). Together, these observations support the idea that loss of IFI 16 function in normal prostate epithelial cells contributes to bypassing of replicative senescence. Remarkably, the accumulation of senescent prostate epithelial cells, which stain for senescenceassociated marker b-galactosidase, has been reported to play a role in the development of the prostatic enlargement associated with benign prostatic hyperplasia (BPH) (Choi et al., 2000; Castro et al., 2003) . Consistent with these reports, our preliminary work indicated that expression of IFI 16 is detectable by immunohistochemistry in prostate tissues derived from BPH but not prostate adenocarcinoma. Further work is in progress to determine whether expression of IFI 16 function in prostate epithelial cells could serve as a molecular marker to follow the severity of BPH in patients and more importantly, to determine whether the loss of IFI 16 function could serve as a reliable marker for development of prostate cancer in an early stage.
To elucidate the molecular mechanisms by which expression of the IFI 16-gene is regulated in normal PrECs, we have isolated a genomic fragment (1.68 Kb) corresponding to the 5 0 -regulatory region of the IFI 16
gene. Sequencing of this genomic DNA fragment and its comparison with sequences in the GenBank revealed the presence of SNPs, raising the possibility that these SNPs might contribute to differential regulation of IFI 16 gene in individuals. Consistent with this possibility, the IFNinduction of IFI 16 gene has been shown to be cell-typeand donor-specific (Schlaak et al., 2002) . In summary, our novel observations support the idea that IFN-inducible IFI 16 from the p200-protein family contributes to cellular senescence of prostate epithelial cells. Since irreversible cell growth arrest associated with cellular senescence represents a major barrier, analogous to apoptosis, which cells must circumvent to become malignant, our observations support the idea that loss of IFI 16 function in prostate epithelial cells may provide a proliferation advantage to cells by bypassing a senescence checkpoint. We suggest that IFI 16 inhibits proliferation of prostate epithelial cells, in part, by upregulating expression of p21
, and by inhibiting E2F-stimulated transcription. Importantly, our observations will serve as a basis to determine whether loss of IFI 16 function could serve as a molecular marker for development of prostate carcinoma.
Materials and methods
PrECs and prostate cancer cell lines
Normal human PrECs were purchased (in culture) from Clonetics (San Diego) at passage 3. Cells were split as suggested by the supplier and maintained in PrEBM culture medium (cat # CC-3165; Clonetics), supplemented with suggested reagents/growth factors and antibiotics. After passage 8, PrECs in culture exhibited a phenotype consistent with replicative senescence: cells became large, flattened with granular cytoplasm (Campisi, 2001) . Human prostate cancer cell lines (LNCaP, DU-145, and PC-3) were purchased from ATCC and maintained in 1640 culture medium supplemented with 10% fetal bovine serum (FBS) and antibiotics.
Plasmids and antibodies
Mammalian expression vector (pCMV-IFI 16B) to express IFI 16B, bacterial expression vectors to express GST-IFI 16 fusion proteins (GST-IFI 16(1-729), , and GST-IFI 16(1-159)) and monoclonal antibodies to IFI 16 have been described (Johnstone et al., 1998) .
RT-PCR and sequencing
Total RNA isolated from PC-3 cells was subjected to one-step RT-PCR, using IFI 16B-specific primers and a kit from Gibco-BRL, as suggested by the supplier. The PCR product was cloned in a TOPO cloning vector (Invitrogen, Carlsbad, CA, USA), to perform DNA sequencing.
Colony-formation assays
Colony-formation assays were performed essentially as described previously . In brief, human prostate cell lines (B10 5 cells in 60-mm plate) were transfected with either empty vector (pCDNA3; 2 mg) or equal amounts of pCDNA3-IFI 16B plasmid (encoding IFI 16B protein) using FuGENE 6 transfection agent. Following 24 h of transfec-tions, cells were split into two 100 mm plates and selected in G418 for about 2 weeks. Colonies exhibiting G418 resistance were stained with crystal violet and counted as described previously .
Reporter assays
Luciferase reporter assays were performed as described previously . In brief, subconfluent cultures of PrECs were transfected using FuGENE 6 transfection reagent (Rosch, Indianapolis, IN, USA) with desired pluc-reporter plasmid (1 mg) and a second reporter pRL-TK (0.1 mg; encoding the Renella luciferase) with appropriate amounts of plasmid encoding the gene of interest. The cells were harvested 45 h after transfections and the firefly luciferase and Renilla luciferase activities were determined (in triplicates) using Dual-Luciferase Reporter Assay kit (from Promega). The firefly-luciferase activity was normalized to Renillaluciferase in order to control for variations in transfections. The luciferase activity in control vector-transfected cells will be considered as 1. Standard error was calculated using three experimental readings.
Flow cytometry
Flow cytometry was performed on single-cell suspensions on adherent (after trypsin and EDTA treatment) as well as the floating cells after pooling them. Briefly, for cell-cycle analysis, cells were stained with propidium iodide (50 mg/ml, Sigma) and subjected to flow cytometry using Coulter Epics XL-MCL flow cytometer as described previously . Apoptosis was measured by the accumulation of cells with a sub-G 1 DNA content.
Indirect immunofluorescence
Human PrECs or PC-3 cells were cultured on glass coverslips in a six-well plate. Cells were fixed with 100% methanol at room temperature and processed for indirect immunofluorescence microscopy to localization of IFI 16, as described previously (Choubey and Lengyel, 1992) . Antibodies to IFI 16 were detected by the secondary anti-mouse IgG-conjugated to rhodamine fluorochrome (Sigma, Cat # T6528).
Binding to GST-fusion proteins
Fusion proteins, in which glutathione transferase protein was fused to various segments of IFI 16B proteins, were produced in bacteria and purified as described previously (Choubey et al., 1996) . The purified fusion proteins bound to glutathionesepharose beads were used in GST-pull-down assays. The assays were performed essentially as described previously (Choubey et al., 1996) . In brief, cell lysates containing equal amounts of proteins were incubated with beads for 30 min at 41C. Beads were washed with wash buffer and the bound proteins were analysed by immunoblotting.
Immunoblotting
Tissue lysates (Protein Medleys) derived from various human tissues were purchased from Clontech (Palo Alto, CA, USA). To prepare cell lysates, cells were collected from plates in PBS and resuspended in a modified RIPA lysis buffer (50 mm TrisHCl, pH 8.0; 250 mm NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitors (leupeptin, 50 mg/ml; Pepstatin A, 50 mg/ml; PMSF, 1 mm), and incubated at 41C for 30 min. The cell lysates were sonicated briefly before centrifugation at 14 000 r.p.m. in a microfuge for 10 min. The supernatants were collected and equal amounts of proteins were processed for immunoblotting as described previously . The IFI 16 monoclonal antibodies have been described (Johnstone et al., 1998) . Antibodies to PKR, p16, p21 WAF1 , pRb, E2F1, and cyclin E were purchased from Santa Cruz Biotech. Inc. (Santa Cruz, CA, USA).
Northern blotting
Total cytoplasmic RNA was isolated from cells and subjected to Northern blotting followed by hybridization with a HindIII 5 0 -fragment of IFI 16B cDNA (nucleotides 1-1192) (Johnstone et al., 1998) . Hybridizations were performed as described previously .
Senescence-associated b-galactosidase assays
These assays were performed essentially as described previously (Dimri et al., 1995) . In brief, cells in culture were fixed using in situ b-galactosidase staining kit (cat # 200384; from Stratagene, La Jolla, CA, USA). Fixed cells were incubated with the staining solution prepared in a buffer (pH 6.0) overnight at 371C. Cells, which stained blue, were considered positive for the activity of senescence-associated b-galactosidase and were counted.
Cell-proliferation assays
Cell proliferation was studied by monitoring the incorporation of 5-bromo-2 0 -deoxy-uridine (BrdU) into cellular DNA using BrdU labeling and detection kit II (from Roche, Indianapolis, IN, USA). We followed the protocol suggested by the supplier. Cells staining positive for the incorporation of BrdU as well as total number of cells were counted in each sample.
